Bayer plans to invest $2.2 billion in a pharmaceutical manufacturing campus in New Albany, Ohio, combining drug substance and finished product production in a modular facility scheduled to enter operation in stages from 2031.
The company expects the development to create around 600 permanent jobs and approximately 1,500 construction roles within New Albany International Business Park. Initial production will support Bayer’s pharmaceutical portfolio across oncology, cardiovascular and renal care, with the site designed so later modules can be added as demand and product requirements change.
The first module is planned for drug substance manufacturing and is due to become operational in 2031, while a second module for finished product manufacturing is scheduled for 2034. Separating the two stages allows Bayer to bring upstream capacity online before completing the later processing needed to turn active material into commercial dosage forms.
Drug substance manufacture creates the active pharmaceutical material to defined chemical and physical specifications, whereas finished product operations combine that material with other ingredients and carry it through formulation, tableting, filling, coating or packaging depending on the medicine involved. The two stages use different equipment and process controls even when they operate on the same campus.
Locating both capabilities together can reduce some transfers between plants and give Bayer more control over timing between production stages, but each operation still requires its own qualified utilities, process equipment, laboratories and environmental controls. Material moving from one module to another must retain traceability and approved status throughout the transfer.
The modular design allows infrastructure to be built in stages rather than constructing the final campus configuration at once, reducing the amount of unused capacity during the early years of operation. Bayer can also adjust later modules if its product mix changes before the 2034 expansion is installed.
Power, water, waste systems, warehousing, laboratories and digital infrastructure nevertheless have to be designed with later expansion in mind, since new manufacturing blocks must be connected without disrupting modules already supplying medicine. An undersized utility network or poorly located service route could turn a modular manufacturing plan into a sequence of disruptive retrofits.
Automation and digital systems will form part of the New Albany design, with equipment control, material movement and production records integrated into the manufacturing route. Pharmaceutical automation is used primarily to improve repeatability and traceability rather than remove technical staff, since every automated process still requires maintenance, calibration and investigation when conditions move outside approved limits.
The projected permanent workforce of around 600 reflects those requirements, with process engineers, maintenance specialists, laboratory scientists, quality personnel, automation engineers and production operators needed alongside conventional site functions. A highly automated line can stop completely when a sensor, control system or utility fails, making engineering response and preventive maintenance part of the plant’s usable capacity.
New Albany has attracted several advanced manufacturing projects because its business park provides large development plots and regional infrastructure, while Bayer’s investment adds another pharmaceutical operation to that industrial base. The site will extend a US network that already includes research and manufacturing activities in several states.
Bayer says it has invested more than $7 billion in US pharmaceutical research, development and manufacturing during the previous five years and describes the country as its fastest growing pharmaceutical market. Adding drug substance capacity in Ohio takes that investment further upstream, giving the company more control over active material required by later manufacturing stages.
Construction will be followed by equipment installation, commissioning, utility qualification, automation testing and process validation before commercial material can be released from the plant. A mechanically complete building therefore remains several technical stages away from becoming usable pharmaceutical capacity.
Production knowledge must also be transferred into New Albany as equipment comes online, with operators and engineers trained against processes that have to perform consistently under routine conditions rather than only during qualification runs. Early batches usually carry greater engineering and quality scrutiny while teams establish how equipment behaves over repeated cycles.
Bringing the first module online in 2031 gives Bayer several years before finished product manufacturing follows in 2034, allowing the drug substance operation to stabilise while later construction continues elsewhere on the campus. Material may continue moving through other plants until both stages are operating in Ohio, so the site will reach its intended integrated form progressively rather than at a single opening.
The $2.2 billion programme creates capacity in phases, beginning with the upstream manufacturing operation due in 2031. Before that first module contributes commercial output, Bayer still has to move it through construction, commissioning and validation and demonstrate that repeated batches remain within the controls required for pharmaceutical supply.
